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Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method in
patients with ST-segment elevation myocardial infarction (STEMI). In patients with STEMI who
cannot undergo timely primary PCI, pharmacoinvasive treatment is recommended, comprising
immediate fibrinolytic therapy with subsequent coronary angiography and rescue PCI if needed.
Improving clinical outcomes following fibrinolysis remains of great importance for the many
patients globally for whom rapid treatment with primary PCI is not possible. For patients with
acute coronary syndrome who underwent primary PCI, the PLATO trial demonstrated superior
efficacy of ticagrelor relative to clopidogrel. Results in the predefined subgroup of patients with
STEMI were consistent with the overall PLATO trial. Patients who received fibrinolytic therapy
in the 24 hours before randomization were excluded from PLATO, and there is thus a lack of
data on the safety of using ticagrelor in conjunction with fibrinolytic therapy in the first
24 hours after STEMI. The TREAT study addresses this knowledge gap; patients with STEMI
who had symptom onset within the previous 24 hours and had received fibrinolytic therapy
(of whom 89.4% had also received clopidogrel) were randomized to treatment with ticagrelor or
clopidogrel (median time between fibrinolysis and randomization: 11.5 hours). At 30 days, tica-
grelor was found to be non-inferior to clopidogrel for the primary safety outcome of Thromboly-
sis in Myocardial Infarction (TIMI)-defined first major bleeding. Considering together the results
of the PLATO and TREAT studies, initiating or switching to treatment with ticagrelor within the
first 24 hours after STEMI in patients receiving fibrinolysis is reasonable.
KEYWORDS
fibrinolysis, reperfusion therapy, ST-segment elevation myocardial infarction, ticagrelor,
TREAT study
1 | INTRODUCTION
1.1 | Reperfusion therapy for patients with
ST-segment elevation myocardial infarction
Guidelines for the treatment of patients with ST-segment elevation
myocardial infarction (STEMI) recommend primary percutaneous
coronary intervention (PCI) as the preferred reperfusion therapy, if it
can be performed in a timely manner.1,2 In patients with STEMI who
cannot undergo timely primary PCI, however, early fibrinolysis also
provides effective reperfusion.3–6 If treatment with primary PCI is
delayed by 2 hours or more relative to treatment with fibrinolysis,
then similar mortality outcomes are observed for both treatment
options.7,8 Thus, if primary PCI cannot be performed within 2 hours of
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STEMI diagnosis, pharmacoinvasive treatment is recommended, com-
prising immediate fibrinolytic therapy with subsequent coronary angi-
ography and either rescue PCI, if there is no evidence of clinical
reperfusion, or elective PCI within 2 to 24 hours, in case of successful
reperfusion.1,2 The efficacy of the pharmacoinvasive treatment strat-
egy is supported by the results of the STREAM trial.3,9 Routine PCI in
asymptomatic patients more than 48 hours after symptom onset is
not recommended.2
In real-world settings, access to primary PCI can be delayed or
made impossible by geographical and economic hurdles, such as long
distances to PCI centers, difficulties with traffic and transportation,
and PCI centers not being open overnight or over weekends, or not
being available at all.10 Delays to providing reperfusion therapy are
common: in two large prospective observational studies, EPICOR
(NCT01171404) and EPICOR Asia (NCT01361386), recruiting 11 559
patients with STEMI from 773 hospitals in 28 countries across
Europe, Latin America, and Asia, the overall median time from symp-
tom onset to reperfusion therapy was 5.8 hours for primary PCI (inter-
quartile range [IQR]: 3.2-13.5 hours) and 3.5 hours for fibrinolysis
(IQR: 2.0-6.0 hours).11 There were large regional variations, with
median time from symptom onset to primary PCI ranging from
3.9 hours in Southern and Northern Europe, South Korea, Hong Kong,
and Singapore, to 20.9 hours in India, and median time to fibrinolysis
ranging from 2.4 hours in Southern Europe to 6.3 hours in India
(Figure 1). Data from the United States indicate that fewer than half
of patients who require transfer from a referral center to a STEMI
receiving-center receive primary PCI within 2 hours of presentation at
the referral center if the interhospital drive time is longer than
30 minutes.6 Registry data from Arabian Gulf countries (Saudi Arabia,
Bahrain, Qatar, Oman, and United Arab Emirates) show a median time
from symptom onset to hospital arrival for patients with STEMI of
between 2.5 and 2.9 hours, with most patients requiring emergency
transfer between treatment centers.12–14
These difficulties and regional variations are reflected in treat-
ments used in clinical practice. In EPICOR and EPICOR Asia, rates of
primary PCI ranged from 25% in India to 66% in Northern Europe, and
of fibrinolysis from 8% in China to 34% in Southeast Asia (Figure 1).11
A large number of patients received no reperfusion therapy at all,
ranging from approximately 20% in Europe, to 40% in Latin America
and China, and 46% in India. Among patients who received any type
of reperfusion therapy, the proportions of patients who received fibri-
nolysis rather than primary PCI were most substantial in Latin America
(55%), India (55%), and Southeast Asia (44%). Similarly, in aggregated
survey data from 37 European Society of Cardiology affiliated coun-
tries, rates of primary PCI and fibrinolysis varied widely, with many
patients with STEMI not receiving any reperfusion therapy.10 In other
settings, treatment options may be even more limited: an observa-
tional study conducted in predominantly rural centers in China sug-
gests that the proportion of patients with STEMI receiving early
reperfusion therapy in this setting is only about 35% (compared with
60% in the centers included in EPICOR Asia).15 In Arabian Gulf coun-
tries and Egypt, 55% to 69% of registry patients with STEMI received
thrombolytic therapy and 10% to 37% underwent PCI.12,16–18 In con-
trast, in France, data from the French FAST-MI registry show that 6%
of patients with STEMI received intravenous fibrinolysis and 71%
underwent primary PCI.19 In Norway, 19% of patients with STEMI
aged less than 80 years were treated with fibrinolysis and 76% with
primary PCI in 2016; the proportion of patients receiving fibrinolytic
therapy was higher in rural than urban centers.20
1.2 | Antiplatelet therapy following reperfusion
Adjunct dual antiplatelet therapy with aspirin and the P2Y12 antago-
nist clopidogrel is used to support reperfusion with fibrinolytic
therapy,1,2 based on results from the CLARITY (NCT00714961) and
COMMIT (NCT00222573) trials.21,22 In CLARITY, patients who pre-
sented within 12 hours of STEMI symptom onset were randomized to
clopidogrel (300 mg loading dose followed by 75 mg daily) or placebo,
received fibrinolytic therapy and underwent an angiogram after 2 to
8 days. Compared with placebo, treatment with clopidogrel resulted
in a 36% reduction in the odds of an infarct-related artery occlusion,
death, or recurrent myocardial infarction by the time of angiogram
(the primary endpoint).22 In COMMIT, patients who presented within
24 hours of an acute myocardial infarction were randomized to clopi-
dogrel (75 mg daily, no loading dose) or placebo; approximately half of
the patients also received fibrinolytic therapy. Compared with pla-
cebo, treatment with clopidogrel resulted in a 9% proportional reduc-
tion in death, re-infarction, or stroke during the treatment period
(mean 15 days in survivors).21 No significant excess risk was observed
with clopidogrel for the composite of fatal bleeds, cerebral bleeds, or
bleeding requiring transfusion.21
For patients who experience an acute coronary syndrome with or
without ST-segment elevation who receive primary PCI, the PLATO
trial (NCT00391872) has demonstrated that the P2Y12 antagonist
ticagrelor is superior to clopidogrel in preventing recurrent myocardial
infarction, stroke or death from vascular causes over 12 months (pri-
mary endpoint; hazard ratio: 0.84; 95% CI: 0.77-0.92; P < 0.001).23 In
patients with STEMI and across various other predefined subgroups,
efficacy results were consistent with the overall PLATO trial.23,24 The
use of ticagrelor did not significantly increase the overall risk of major
bleeding relative to the use of clopidogrel, although ticagrelor was
associated with significantly higher rates of major bleeding not related
to coronary-artery bypass grafting, including fatal intracranial
bleeding.23
Patients who had received fibrinolytic therapy in the 24 hours
before randomization were excluded from PLATO23 so there is thus a
lack of data on the safety of using ticagrelor in conjunction with fibri-
nolytic therapy in the first 24 hours after STEMI. The 2013 American
College of Cardiology/American Heart Association guidelines for the
management of STEMI highlighted this data gap, noting that the co-
administration of P2Y12 antagonists other than clopidogrel with fibri-
nolytic therapy has not been prospectively studied.1 As a result, the
European label for ticagrelor currently cautions against the concomi-
tant use of other medicinal products that may increase bleeding risk,
including fibrinolytics, within 24 hours of ticagrelor dosing.25 The
European guidelines for the treatment of STEMI recommend clopido-
grel immediately after fibrinolysis; however, after a safety period, set
at 48 hours, no grounds are found to consider that a more potent
P2Y12 inhibitor would increase the risk of bleeding, or fail to exert a
clinically relevant benefit in line with the results of PLATO.2 Thus, for
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patients who receive fibrinolysis and subsequently undergo PCI, the
guidelines note that a switch from clopidogrel to prasugrel or ticagre-
lor may be considered 48 hours after fibrinolysis.
2 | TREAT STUDY
2.1 | Design and methodology
The TREAT study (NCT02298088) has been designed to provide evi-
dence regarding the safety of ticagrelor relative to clopidogrel in
patients with STEMI treated with fibrinolytics.26,27 TREAT is an inter-
national, phase 3 study run by the Research Institute of the Hospital
do Coração, São Paulo, Brazil. It was started in August 2015 and
enrolled 3799 patients from participating centers in Argentina,
Australia, Brazil, Canada, China, Colombia, New Zealand, Peru, Russia,
and Ukraine.
Patients aged between 18 and 75 years with STEMI who had
symptom onset within the previous 24 hours and had received fibri-
nolytic therapy were randomized to treatment with ticagrelor or clopi-
dogrel (Figure 2). The maximum time of 24 hours from symptom
onset was chosen to fill the existing data gap, because patients who
had received fibrinolytic therapy in the previous 24 hours were
excluded from the PLATO trial. Patients received a loading dose of
the study medication (ticagrelor: 180 mg; clopidogrel: 300-600 mg) as
early as possible after the index event and not more than 24 hours
after the event, and then received maintenance doses thereafter (tica-
grelor: 90 mg twice daily; clopidogrel: 75 mg once daily). Patients who
had received clopidogrel at the time of fibrinolysis prior to randomiza-
tion were still eligible to participate, and if randomized to the
FIGURE 1 Results of the global EPICOR and EPICOR Asia studies. A, Use of reperfusion therapy; B, median time to primary PCI; and C, median
time to fibrinolysis. Reproduced from Rossello et al. 2017.11 Abbreviations: IQR, interquartile range; PCI, percutaneous coronary intervention
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clopidogrel arm of the study could be given an additional loading dose
at the discretion of the investigating physician. Follow-up visits were
scheduled at hospital discharge or on the seventh day after discharge,
and then at 30 days, 6 months, and 12 months after randomization.
The primary outcome of the TREAT study is safety as a measure
of time to Thrombolysis In Myocardial Infarction (TIMI)-defined first
major bleeding at 30 days, with a margin for non-inferiority set at an
absolute difference of 1.0% (one-sided α: 2.5%). Secondary endpoints
are other bleeding events according to TIMI, PLATO or Bleeding Aca-
demic Research Consortium (BARC) definitions, and exploratory end-
points include a composite of recurrent myocardial infarction, stroke
or death from vascular causes, the same composite outcome with the
addition of recurrent ischemia, transient ischemic attack or other arte-
rial thrombotic events, individual components of the composite effi-
cacy outcome, and all-cause mortality.
2.2 | Results overview
Detailed 30-day results of the TREAT study have been published.26
Briefly, ticagrelor was found to be non-inferior to clopidogrel for the
primary outcome of TIMI-defined major bleeding at 30 days. The
median time between fibrinolysis and randomization to ticagrelor or
clopidogrel treatment was 11.4 hours (ticagrelor: 11.4 hours; clopido-
grel: 11.5 hours), and 89.4% of patients had received clopidogrel prior
to randomization. The mean age of patients was 58.0 years (SD: 9.5),
and baseline characteristics were well balanced between the two
groups. The proportions of patients receiving different fibrinolytic
therapies were: 39.6% tenecteplase, 19.7% alteplase, 16.8% reteplase,
7.0% prourokinase, 6.9% urokinase, 5.7% streptokinase, and 4.2%
other. At 30 days, TIMI major bleeding had occurred in 0.73% of
patients receiving ticagrelor and 0.69% of those receiving clopidogrel
(absolute difference: 0.04%; 95% CI: −0.49-0.58; P < 0.001 for non-
inferiority) (Figure 3). Non-inferiority was similarly demonstrated for
major bleeding defined according to the PLATO trial and for BARC
types 3 to 5 bleeding. Patients in the ticagrelor and clopidogrel groups
experienced similar rates of fatal bleeding (0.16% vs 0.11%, respec-
tively; P = 0.67) and intracranial bleeding (0.42% vs 0.37%, respec-
tively; P = 0.82). For other categories of bleeding events, statistically
significantly higher rates of total bleeding (5.38% vs 3.82%, respec-
tively; P = 0.02) and PLATO-defined minimal bleeding (3.24% vs
2.01%, respectively; P = 0.02) were seen for ticagrelor relative to clo-
pidogrel, and rates of TIMI minimal bleeding were also numerically
higher with ticagrelor than with clopidogrel (2.46% vs 1.59%, respec-
tively; P = 0.06). The rates of bleeding in the ticagrelor and clopidogrel
groups are consistent with findings from several smaller trials compar-
ing ticagrelor and clopidogrel in patients with STEMI treated with
fibrinolytics, as reported in a recently published systematic review and
meta-analysis.28–32
Regarding efficacy, the study lacked statistical power to detect a
significant difference at 30 days. The composite outcome of death
from vascular causes, myocardial infarction or stroke occurred at a
similar rate at 30 days in patients receiving ticagrelor and those
FIGURE 2 TREAT study design. Reproduced from Berwanger
et al. 2018.27 Abbreviations: STEMI, ST-segment elevation myocardial
infarction
FIGURE 3 TIMI major, PLATO major and BARC type 3 to 5 bleeding at 30 days among patients receiving ticagrelor and patients receiving
clopidogrel in the TREAT study. Reproduced from Berwanger et al. 2018.26 Abbreviations: BARC, bleeding academic research consortium; CI,
confidence interval; PLATO, Platelet Inhibition and Patient Outcomes; TIMI, Thrombolysis in Myocardial Infarction
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receiving clopidogrel (4.0% vs 4.3%, respectively; P = 0.57). Similarly,
no statistically significant difference was observed between the two
patient groups in other individual or composite efficacy outcomes.
Despite the lack of statistical power, the results from the TREAT study
are consistent with those from the PLATO STEMI analysis, which sug-
gested that clinical benefit was observed only after the first month of
treatment.24
3 | CLINICAL IMPLICATIONS
Given the superior efficacy of ticagrelor relative to clopidogrel demon-
strated in PLATO for patients receiving primary PCI, and its non-
inferior safety demonstrated in the TREAT study when given within
24 hours of fibrinolysis, the length of the period during which clopido-
grel is recommended following fibrinolysis before switching to ticagre-
lor or prasugrel (currently 48 hours in the European guidelines)2
should be reconsidered. The TREAT study provides strong evidence
that the administration of ticagrelor will not increase the risk of major
bleeding in patients treated with fibrinolytics, even if undertaken very
soon after the thrombolytic index event. Physicians should decide on
a patient-by-patient basis as to whether such a switch is likely to be
of benefit.
Two aspects of the design of the TREAT study should be noted.
First, dosing with the study drug did not occur immediately after the
administration of fibrinolysis. The median time from fibrinolysis to ran-
domization was approximately 11.5 hours and the majority of patients
(89.4%) received un-blinded clopidogrel during this period.26 The time
from fibrinolysis to randomization was comparable to that observed in
the COMMIT study (personal communication, data on file). For
patients who received clopidogrel with fibrinolysis who were subse-
quently randomized to clopidogrel, the TREAT study protocol allowed
for the administration of a second loading dose of 300 mg, at the dis-
cretion of the treating physician. The study was designed in this way
to allow for questions of logistics and feasibility (transfer times from
smaller receiving centers to larger study centers), while also filling the
data gap following PLATO regarding the safety of the use of ticagrelor
within 24 hours of fibrinolysis. It is of note that even in the subgroup
of patients who were randomized within 4 hours of fibrinolysis, no
significant difference was found between ticagrelor and clopidogrel
for the primary safety endpoint of TIMI major bleeding (P = 0.73), or
for PLATO major bleeding or BARC types 3 to 5 bleeding.26 However,
the smaller size of this subgroup analysis reduces the statistical power
of the trial to detect such a difference.
Second, efficacy endpoints were exploratory only and the trial
lacked statistical power to detect significant differences. The sample
size for the trial was chosen to provide greater than 90% statistical
power for the primary safety outcome, with a projected TIMI major
bleeding rate at 30 days of 1.2%. Twelve-month follow-up of the
TREAT study is ongoing, and will provide further information regard-
ing the relative efficacy of the two treatments.
Given the large number of patients around the world for whom
rapid treatment with primary PCI is not possible, the question of how
to improve clinical outcomes following fibrinolysis remains of great
importance.11 There is growing recognition of the effectiveness of a
pharmacoinvasive treatment strategy to ensure that rapid reperfusion
is achieved. The wide geographic coverage and heterogeneity of the
patient population in the TREAT study, which did not specify a spe-
cific fibrinolytic agent for investigation, and left several treatment
decisions to the discretion of the investigating physicians, allows for a
high degree of external validity.26 The results can thus be applied to a
wide range of patient populations worldwide.
A number of important questions remain to be answered, some of
which may be addressed by secondary analyses of the TREAT data
set, while others depend on the conduct of future randomized con-
trolled trials. Nevertheless, the current trial results represent a signifi-
cant step forward in informing the optimal treatment of patients with
STEMI. Considering together the results of the PLATO and TREAT
studies, initiating or switching to treatment with ticagrelor within
24 hours of receiving fibrinolysis in patients with STEMI is a reason-
able approach to undertake.
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